All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-09-16T10:26:40.000Z

Zanubrutinib granted accelerated approval by the FDA for the treatment of patients with R/R MZL

Sep 16, 2021
Share:

Bookmark this article

On September 15, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib for the treatment of adult patients with relapsed or refractory marginal zone lymphoma, who had at least one prior treatment with an anti–CD20-based regimen. Zanubrutinib is a next-generation, irreversible Bruton’s tyrosine kinase (BTK) small molecule inhibitor and is optimized for a higher specificity to improve efficacy and safety. BTK is instrumental in B-cell receptor signaling, a known driver in the development of marginal zone lymphoma.

The approval was based on clinical data from the single-arm, open-label, multicenter, phase II MAGNOLIA trial (NCT03846427), which you can read more about here for information on study design, patient characteristics, key outcomes, and adverse events. Additional supporting data came from the phase I/II trial of BGB-3111-AU-003 (NCT02343120), that investigated zanubrutinib in patients with B-cell malignancies. Continued approval might need verification of clinical benefit in a confirmatory trial.

Zanubrutinib has also been approved by the FDA for other indications including Waldenström’s macroglobulinemia, relapsed/refractory mantle cell lymphoma, and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) by the Chinese National Medical Products Administration (NMPA).

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox